EUVIMEDEUVIMED entdecken
Crossref

Dyslipidemia: Diabetes lipid therapies

Haider Rehan, Mehdi Asghar, Kumari Das Geetha, Ahmed Khanzada Zameer, Zameer Khanzada Sambreen

i-manager's Journal on Life Sciences · 2024

DOI: 10.26634/jls.3.1.20942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift i-manager's Journal on Life Sciences, 2024. Verfasst von Haider Rehan und 4 weiteren Autor:innen. Die Arbeit nennt 60 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dyslipidemia caused by abnormal lipid profiles significantly increases the risk of cardiovascular disease (CVD) in individuals with diabetes. Effective management necessitates a comprehensive approach that encompasses lifestyle modifications and pharmacological intervention. Lifestyle adjustments such as adopting a healthy diet and engaging in regular physical activity play a crucial role in managing dyslipidemia. Avoiding foods high in saturated fat, trans fat, and cholesterol, while incorporating high-fiber foods and omega-3 fatty acids, helps regulate lipid profiles. Regular exercise increases high-density lipoprotein (HDL) cholesterol levels, promotes weight loss, and aids in managing dyslipidemia. While behavioral changes are beneficial, pharmacological treatments are pivotal. Statins are the cornerstone for managing dyslipidemia in diabetic patients, regardless of standard lipid levels, due to their ability to lower low-density lipoprotein (LDL) cholesterol levels. Additional lipid-lowering agents such as ezetimibe, bile acid sequestrants, and PCSK9 inhibitors may complement treatment strategies to improve lipid profiles. The advancements include new formulations of antidiabetic medications that demonstrate favorable effects on lipid parameters in diabetic patients. Sodiumglucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) not only provide cardiovascular benefits but also aid in lowering lipid levels. SGLT-2 inhibitors reduce LDL cholesterol and triglyceride levels, while GLP-1 RAs primarily target triglycerides and LDL cholesterol levels.

Zitieren

APA

Rehan, H., Asghar, M., Geetha, K. D., Zameer, A. K., & Sambreen, Z. K. (2024). Dyslipidemia: Diabetes lipid therapies. i-manager's Journal on Life Sciences. https://doi.org/10.26634/jls.3.1.20942

Vancouver

Rehan H, Asghar M, Geetha KD, Zameer AK, Sambreen ZK. Dyslipidemia: Diabetes lipid therapies. i-manager's Journal on Life Sciences. 2024. doi:10.26634/jls.3.1.20942

BibTeX
@article{Rehan2024,
  author = {Rehan, Haider and Asghar, Mehdi and Geetha, Kumari Das and Zameer, Ahmed Khanzada and Sambreen, Zameer Khanzada},
  title = {Dyslipidemia: Diabetes lipid therapies},
  journal = {i-manager's Journal on Life Sciences},
  year = {2024},
  doi = {10.26634/jls.3.1.20942}
}
Kostenlos starten →